Skip to main content
. Author manuscript; available in PMC: 2018 Jan 10.
Published in final edited form as: Circulation. 2016 Nov 23;135(2):153–165. doi: 10.1161/CIRCULATIONAHA.116.025471

Figure 1. CAC distribution by anti-hypertension treatment status in the primary MESA sample overall (3,733 U.S. adults aged 45 to 84 years with Systolic BP 120-180 mmHg) and the SPRINT-eligible subsample (N=1,394).

Figure 1

A) Primary Sample Untreated

B) Primary Sample on BP treatment

C) Sprint subsample Untreated

D) Sprint subsample on BP treatment

* p value comparing CAC level among treated to untreated in the primary sample

† p value comparing CAC level among treated to untreated in SPRINT sub-sample

OSZAR »